Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for HLB Pharmaceutical Co., Ltd. (047920:KRX), powered by AI.
HLB Pharmaceutical Co., Ltd. is currently trading at ₩17,300. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for HLB Pharmaceutical Co., Ltd. on Alpha Lenz.
HLB Pharmaceutical Co., Ltd.'s P/E ratio is 271.5.
“HLB Pharmaceutical Co., Ltd. trades at a P/E of 271.5 (premium valuation) with modest ROE of 2.0%. 3Y revenue CAGR of 29.7% highlights clear growth momentum.”
Ask for details →HLB Pharmaceutical Co., Ltd. is a comprehensive entity in the pharmaceuticals sector, primarily focused on the research, development, and distribution of pharmaceutical products. This company plays a vital role in advancing healthcare by delivering a range of medical solutions that span various therapeutic areas. HLB Pharmaceutical is recognized for its commitment to innovation in drug discovery and biopharmaceuticals. With a strategic emphasis on both domestic and international markets, the company impacts numerous sectors, including biotechnology, healthcare services, and medical technology. Its operations involve intricate processes of clinical trials, regulatory compliance, and manufacturing excellence. Positioned as a key player within the pharmaceutical market, HLB Pharmaceutical Co., Ltd. contributes to the globalization of healthcare, catering to an array of health needs across different demographics. The firm's ongoing projects and partnerships make it a significant entity in the pursuit of medical advancements, especially in emerging markets where healthcare demand is rapidly increasing.
“HLB Pharmaceutical Co., Ltd. trades at a P/E of 271.5 (premium valuation) with modest ROE of 2.0%. 3Y revenue CAGR of 29.7% highlights clear growth momentum.”
Ask for details →HLB Pharmaceutical Co., Ltd. (ticker: 047920) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $567.4B.
The current price is ₩17,300 with a P/E ratio of 271.49x and P/B of 4.71x.
ROE is 1.97% and operating margin is 1.08%. Annual revenue is $137.1B.